How the COVID-19 Vaccine for Children Differs From Adults’

 

Key Points:

  • Pfizer recently announced its vaccine for children is more than 90% effective.
  • In vitro diagnostics company Todos Medical announced the launch of their new COVID-19 antibody blood test which will allow unvaccinated and vaccinated people to monitor their immunity levels to the virus.
  • Healthcare professionals weigh the utility of this type of testing given the amount of at-risk people they interact with on a daily basis.

Commentary:

The next step in the fight against the COVID-19 virus has been the approval of the vaccine for children. Most recently, Pfizer announced that the vaccine that was approved for children is 90 percent effective against COVID-19. Now that the children’s vaccine is here, what was its development like compared to the one for adults? Was it easier or harder? We sat down with Gerald Commissiong, CEO of Todos Medical, to get insight into how the industry has approached the task of vaccine research and testing for different demographics.

MarketScale also asked Commissiong about the recent announcement by Todos about the launch of its new COVID-19 antibody blood test, which will allow unvaccinated and vaccinated people to monitor their immunity levels to the virus. What role will such a test play in the larger ecosystem of COVID treatment and mitigation?

Abridged Thoughts:

Initially, it was thought, although it’s not clear why it was thought, that children were not going to be affected by COVID in the same manner that adults were. As a result of that, the primary focus was really adults who were traveling from place to place, country to country who can spread the disease.

And the focus was on being able to really get people back into the office, back to work. What we found, obviously, is that getting back to work requires children to be able to get back to school. And so as we’ve made progress with the initial set of vaccines and really an undefined, unknown dosing schedule that has been figured out through real world decisions by different countries to do different things than the clinical trials, that kind of approach could have been disastrous in children because we know that their immune systems are not anywhere near as developed and that potentially impacting their immune systems in a robust way very early on in development could have significant long term impacts.

Because of that, I think correctly, everyone focused on developing an effective and safe vaccine for adults and then began to think through how to use the data from adults to develop for kids. There was some acceleration in the 12 to 15 year age gap with the Pfizer vaccine. I think that is being rethought extensively now, given some of the data and the younger kids where there is no evidence of myocarditis with a much lower dosing schedule that could potentially be even further reduced with lengthening the spacing between doses.

More Stories Like This:

Should the COVID-19 Vaccine’s Intellectual Property Be Accessible for Everyone?

Is It Time to Revamp the Drug Development Pipeline?

Follow us on social media for the latest updates in B2B!

Image

Latest

future of healthcare
Leading Through Change: Dr. Kevin Stevenson on Workforce, Innovation, and the Future of Healthcare
October 1, 2025

Healthcare is at a critical turning point, where staffing pressures, shrinking reimbursements, and rising patient expectations are reshaping the future of healthcare. According to the AACN Nursing Workforce Fact Sheet, the federal government projects more than 203,000 new registered nurse positions will be created annually from 2021 to 2031, reflecting high demand from an…

Read More
Non-traditional students
Holistic Support in Higher Ed: Why Non-Traditional Students Need More Than Just Financial Aid
October 1, 2025

Non-traditional students—adult learners, student parents, veterans, and first-generation college-goers—are carrying heavier burdens than ever. Upswing’s 2024 Ana Insights Report found that nearly nine in ten students intended to complete a FAFSA application, while many also sought help with essentials like food, housing, and bill payments. Perhaps most concerning, students expressed declining confidence in higher…

Read More
EAA AirVenture
@EAA AirVenture 2025 – Lori Barger & Larry Schaack Talk Communication & Safety
October 1, 2025

Nestled in the shaded quiet of Oshkosh’s Seaplane Base, there exists a side of EAA AirVenture that many attendees never see. Unlike the bustling main grounds, the Seaplane Base operates for just one week each year, transforming from an unused shoreline into a hub of aviation activity. It takes hundreds of volunteers and days of…

Read More
Seaplanes
Jim Zirbel at @EAA AirVenture 2025 | Keeping Seaplanes Connected & Safe
October 1, 2025

At the heart of EAA AirVenture 2025, the Seaplane Base offers a unique glimpse into aviation’s most delicate dance—where water and air meet. Unlike traditional runways, this floating airfield demands a constant balance of precision, coordination, and communication. Here, pilots don’t just rely on their own skill; they depend on an entire team of volunteers…

Read More